Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
Azetukalner Phase 3 Results Expected
Azetukalner • Major Depressive Disorder
Target Indication
Major Depressive Disorder
Clinical Trial
Last updated: 12/4/2025
XENE
Xenon Pharmaceuticals Inc.